Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

Launched by MEDICAL UNIVERSITY OF VIENNA · May 24, 2024

Keywords

ClinConnect Summary

The OLIGOMET study is looking into the best ways to treat patients with oligometastatic prostate cancer, which means their cancer has spread just a little bit, often to a few spots in the bones or lungs. This study is important because it uses a special type of imaging called PSMA PET, which is better at finding these small areas of cancer compared to traditional imaging methods. Researchers want to gather real-world information about how effective local treatments, like surgery or radiation therapy, are for these patients.

To participate in this study, men aged between 65 and 74 who have been diagnosed with oligometastatic prostate cancer using PSMA PET imaging may be eligible. Key criteria include having a limited number of cancer spots (like 5 or fewer in the bones or 3 or fewer in the lungs) and having undergone local treatment. Participants will help researchers understand the safety and effectiveness of these treatments by contributing to a database that collects valuable clinical data. This study is not yet recruiting, but it aims to improve future care for patients with similar diagnoses.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Oligometastatic prostate cancer diagnosed using PSMA PET defined as cM1a and/or cM1b with ≤5 osseous metastases and/or M1c with ≤3 lung lesions, with or without cN positivity.
• • Oligometastatic prostate cancer treated with primary local therapy such as radical prostatectomy or radiation therapy.
• • Any Gleason Score, any cT stage, any PSA
• Exclusion Criteria:
• • Visceral metastases (apart from lungs).
• • Neoadjuvant therapy prior to first PSMA PET.
• • Non-metastatic prostate cancer.
• • Patients who did not undergo imaging before local treatment.